Antithrombotic Drugs and Vascular Surgery

Abstract

Get full access to this article

View all access options for this article.

References

Harker LA , Gent M. The use of agents that modify platelet function in the management of thrombotic disorders. In Colman RW , Hirsh J , Marder VJ , Salzman EW , eds. Hemostasis and Thrombosis, 2nd ed. Philadelphia : JB Lippincott, 1987 , pp 1438-1456.

Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 296:320-333, 1988.

O'Reilly RA Therapeutic modalities for thrombotic disorders. In Colman RW , Hirsh J , Marder VJ , Salzman EW , eds. Hemostasis and Thrombosis , 2nd ed. Philadelphia: JB Lippincott, 1987 , pp 1367-1372.

Rosenberg RD Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 87(3B):2S-9S, 1989.

Rowland M. , Riegelman S. , Harris PA , et al. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 61:379, 1972.

Ali M. , McDonald JWD , Thiessen JJ , Coates PE Plasma acetylsalicylate and salicylate and enteric-coated aspirin . Stroke 11:9-13, 1980.

Levy G. Clinical pharmacokinetics of aspirin. Pediatrics 62:867, 1978.

Jakubowski JA , Stampfer MJ , Vaillancourt R. , et al. Cumulative anti-platelet effect of low-dose enteric-coated aspirin. Br J Haematol 60:635-642, 1985.

Cohen A. Fecal blood loss and plasma salicylate study of salicylic acid and aspirin . J Clin Pharmacol 19:242-247, 1979.

10.

Fromm D. Salicylate and gastric mucosal damage. Pediatrics 62:938, 1978.

11.

UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Interim results. Br Med J 296:316-320, 1988.

12.

Roth GJ , Majerus PW The mechanism of the effect of aspirin on human platelet . I. Acetylation of a particulate fraction protein. J Clin Invest 56:624, 1975.

13.

Roth GJ , Stanford N. , Majerus PW Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 73:3073, 1975.

14.

Burch JW , Stanford N. , Majerus PW Inhibition of platelet prostaglandin synthetase by oral aspirin . J Clin Invest 61:314, 1978.

15.

Gorman RR , Fitzpatrick FA , Miller OV A selective thromboxane synthetase inhibitor blocks the cyclic AMP lowering activity of PGH2. Biochem Biophys Res Commun 79:305, 1977.

16.

Weiss HJ , Aledort LM , Kochwa S. The effect of salicylates on the hemostatic properties of platelet in man . J Clin Invest 47:2169, 1968.

17.

Wong LT , Zawidzka Z. , Thomas RB Effect of acetylsalicylic acid, sulphinpyrazone and their combination of collagen-induced platelet aggregation in guinea pigs. Pharmacol Res Commun 10:939, 1979.

18.

Packham MA Stages in the interaction of platelets with collagen. Thromb Haemost 36: 269, 1976.

19.

Packham MA , Kinlough-Rathbone RL , Reimers HJ , et al. Mechanisms of platelet aggregation independent of adenosine diphosphate. In Silver MJ , Smith JB , Kocsis JJ , eds. Prostaglandins in Hematology. New York: Spectrum Publishing, 1977 , p 247.

20.

Tschopp ThB. Aspirin inhibits platelet aggregation on, but not adhesion to, collagen fibrils: An assessment of platelet adhesion and deposited platelet mass by morphometry and 51Cr-labelling. Thromb Res 11:619, 1977.

21.

Patrignani P. , Fiblabozzi P. , Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366, 1982.

22.

Karwande SV , Weksler BB , Gay WA , et al. Effect of preoperative antiplatelet drugs on vascular prostacyclin synthesis. Ann Thorac Surg 43:318-322, 1987.

23.

Hirsh J. Progress review: The relationship between dose of aspirin, side-effects and antithrombotic effectiveness. Stroke 16:1-4, 1985.

24.

Mills DCB. Platelet aggregation and the adenylate cyclase system. In Mills DCB , Pareti FI , eds. Platelets and Thrombosis. London : Academic Press, 1977, p 63.

25.

Bunag RD , Doublas R. , Imai RM Influence of a pyrimidopyrimidine derivative on deamination of adenosine by blood. Circ Res 15:83, 1964.

26.

Ally AI , Manku MS , Horrobin DG , et al. Dipyridamole: A possible potent inhibitor of thromboxane A2 synthetase in vascular smooth muscle. Prostaglandins 14:607, 1977.

27.

Emmons PR , Harrison MJG , Honour AJ , et al. Effect of dipyridamole on human platelet behaviour. Lancet 2:603, 1965.

28.

Zucker MB , Peterson J. Effect of acetylsalicylic acid, other nonsteroidal antiinflammatory agents and dipyridamole on human blood platelets. J Lab Clin Med 76:66, 1970.

29.

Harker LA Platelet survival time: Its measurement and use. In Spaet TH , ed. Progress in Hemostasis and Thrombosis, vol 4. New York : Grune & Stratton, 1978, pp 321-347.

30.

FitzGerald GA Dipyridamole. N Engl J Med 316:1247-1257, 1987.

31.

Aberg M. , Hedner U. , Bergentz SE The antithrombotic effect of dextran. Scand J Haematol 34:61, 1979.

32.

Weiss HJ The effect of clinical dextran on platelet aggregation, adhesion and ADP release in man: In vivo and in vitro studies. J Lab Clin Med 69:37, 1967.

33.

Aberg M. , Hedner U. , Bergentz SE Effect of dextran on factor VIII (antihemophilic factor) and platelet function . Ann Surg 189:182-243, 1979.

34.

Muzaffar TZ , Stalker AL , Bryce WAJ , et al. Dextrans and fibrin morphology. Nature 238: 288-290, 1972.

35.

Dhall TZ , Bryce WAJ , Dhall DP Effects of dextran on the molecular structure and tensile behaviour of human fibrin. Thromb Haemost 35:737-745, 1976.

36.

Aberg M. , Bergentz SE , Hedner U. The effect of dextran on the lysability of ex vivo thrombi. Ann Surg 181:342-345, 1975.

37.

Shoenfeld NA , Elldrup-Jorgensen J. , Connolly R. , et al. The effect of low molecular weight dextran on platelet deposition onto prosthetic materials . J Vasc Surg 5:76-82, 1987.

38.

Ring J. , Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes . Lancet 1:466, 1977.

39.

Defreyn G. , Bernat A. , Delebassee D. , Maffrand J-P. Pharmacology of ticlopidine: A review. Semin Thromb Hemost 15(2):159-166, 1989.

40.

Feliste R. , Delebassee D. , Simon MF , et al. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res 48:403-415, 1987.

41.

Gachet C. , Stierle A. , Bouloux C. , et al. The thienopyridine PCR 4099 inhibits the ADP aggregation pathway of human platelets by interfering with the binding of fibrinogen to the glycoprotein IIb-IIIa complex [abstr]. Thromb Haemost 58:211, 1987.

42.

Ellis DJ , Roe RL , Bruno JJ , et al. The effects of ticlopidine hydrochloride on bleeding time and platelet function in man [abstr]. Thromb Haemost 46:1973, 1981.

43.

Hass WK , Easton JD , Adams HP Jr , et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321:501-507, 1989.

44.

Gent M. , Easton JD , Hachinski VC , et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1:1215-1220, 1989 .

45.

Panak E. , Maffrand J-P. , Picard-Fraire C. , et al. A promise for the prevention and treatment of thrombosis and its complications. Haemostasis 13(Suppl 1):1-52, 1983.

46.

Palareti G. , Poggi M. , Torricelli P. , et al. Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease . Thromb Res 52:621-629, 1988.

47.

Arcan JC , Panak E. Ticlopidine in the treatment of peripheral occlusive arterial disease . Semin Thromb Hemost 15:167-170, 1989.

48.

Balsano F. , Coccheri S. , Libretti A. , et al. Ticlopidine in the treatment of intermittent claudication: A 21-month double-blind trial. J Lab Clin Med 114:84-91, 1989.

49.

Szilagyi DE , Elliott JP , Hageman JH , et al. Biologic fate of autogenous vein implants as arterial substitutes: Clinical, angiographic and histopathologic observations in femoropopliteal operations for atherosclerosis. Ann Surg 178:232-246, 1973.

50.

Hagen PO , Wang ZG , Mikat EM , et al. Antiplatelet therapy reduces aortic intimal hyperplasia distal to small-diameter vascular prostheses (PTFE) in nonhuman primates. Ann Surg 195:328-339, 1982.

51.

McCann RL , Hagen PO , Fuchs JCA. Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts. Ann Surg 191:238-243, 1980.

52.

Metke MP , Lie JT , Fuster V. , et al. Reduction of intimal thickening in canine coronary bypass vein grafts with dipyridamole and aspirin. Am J Cardiol 43:1144-1148, 1979.

53.

Clowes AW , Karnovsky MJ Failure of certain antiplatelet drugs to affect myointimal thickening following arterial injury. Lab Invest 36:452-458, 1977.

54.

Bomberger RA , DePalma RG , Ambrose TA , et al. Aspirin and dipyridamole inhibit endothelial healing. Arch Surg 117:1459-1464, 1982 .

55.

Unni KK , Kottke BA , Titus JL , et al. Pathologic changes in aortocoronary saphenous vein grafts. Am J Cardiol 34:526-532, 1974.

56.

Fuster V. , Chesebro JH Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease. Circulation 73:227-232, 1986.

57.

Goldman MD , Simpson D. , Hawker RJ , et al. Aspirin and dipyridamole reduced platelet deposition on prosthetic femoro-popliteal grafts in man. Ann Surg 198:713-716, 1983.

58.

Pumphrey CW , Chesebro JH , Dewanjee MK , et al. In vivo quantitation of platelet deposition on human peripheral arterial bypass grafts using indium-111—labeled platelets: Effect of dipyridamole and aspirin. Am J Cardiol 51:796-801, 1983.

59.

Stratton JR , Ritchie JL Failure of ticlopidine to inhibit deposition of indium-111I-labeled platelets on Dacron prosthetic surfaces in humans. Circulation 69:677-683, 1984.

60.

Stratton JR , Ritchie JL The effects of sulfinpyrazone on platelet deposition on Dacron vascular grafts in man. Am Heart J 109:453-457, 1985.

61.

Stratton JR , Ritchie JL Reduction of indium-111 platelet deposition on Dacron vascular grafts in humans by aspirin plus dipyridamole . Circulation 73:325-330, 1986.

62.

Goldman M. , Norcott HC , Hawker RJ , et al. Platelet accumulation on mature Dacron grafts in man. Br J Surg 69:S38-S40, 1982.

63.

Mayer JE , Lindsay WG , Castaneda W. , et al. Influence of aspirin and dipyridamole on patency of coronary artery bypass grafts. Ann Thorac Surg 31:204-210, 1981.

64.

Chesebro JH , Clements IP , Fuster V. , et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations: Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 307:73-78, 1982.

65.

Chesebro JH , Fuster V. , Elveback LR , et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 310:209-214, 1984.

66.

Lorenz RL , Schacky CV , Weber M. , et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): Effects on platelet aggregation and thromboxane formation. Lancet 1:1261-1264, 1984.

67.

Brown BG , Cukingnan RA , DeRouen T. , et al. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation 72:138-146, 1985.

68.

Rajah SM , Salter MCP , Donaldson DR , et al. Acetvlsalicvlic acid and dipyridamole improve the early patency of aorto-coronary bypass grafts: A double-blind, placebo-controlled, randomized trial. J Thorac Cardiovasc Surg 90:373-377, 1985.

69.

Goldman S. , Copeland J. , Moritz T. , et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: Results of a Veterans Administration Cooperative Study Circulation 77:1324-1332, 1988.

70.

Pfisterer M. , Jockers G. , Regenass S. , et al. Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion . Lancet 2:1-6, 1989.

71.

Pantely GA , Goodnight SH , Rahimtoola SH , et al. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: A controlled, randomized study . N Engl J Med 301:962-966, 1979.

72.

McEnany MT , Salzman EW , Mundth ED , et al. The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery. J Thorac Cardiovasc Surg 83:81-89, 1982.

73.

Sharma Gvrk , Khuri SF , Josa M. , et al. The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency . Circulation 68 (Suppl II):218-221, 1983.

74.

Brooks N. , Wright J. , Sturridge M. , et al. Randomised placebo-controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion. Br Heart J 53:201-207, 1985.

75.

Sethi GK , Copeland JG , Goldman S. , et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 15: 15-20, 1990.

76.

Green RM , Roedersheimer R. , DeWeese JA Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery 92:1016-1026, 1982 .

77.

Goldman M. , Hall C. , Dykes J. , et al. Does 111indium-platelet deposition predict patency in prosthetic arterial grafts? Br J Surg 70:635-638, 1983.

78.

Kohler TR , Kaufman JL , Kacoyanis G. , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery 96:462-466, 1984.

79.

Clyne CAC , Archer TJ , Atuhaire LK , et al. Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. Br J Surg 74:246-248, 1987.

80.

McCollum C. , Alexander C. , Kenchington G. , et al. Antiplatelet drugs in femoro-popliteal vein bypass: A multicentre trial. J Vasc Surg (in press).

81.

Hennekens CH , Buring JE , Sandercock P. , et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80:749-756, 1989.

82.

Kretschmer G. , Pratschner T. , Prager M. , et al. Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy: Analysis of the clinical series followed by a controlled trial. Ann Surg 211:317-322, 1990.

83.

Rutherford RB , Jones DN , Bergentz SE , et al. The efficacy of dextran-40 in preventing early postoperative thrombosis following difficult lower extremity bypass . J Vasc Surg 1: 765-772, 1984.

84.

Kretschmer G. , Wenzl E. , Piza E. , et al. The influence of anticoagulant treatment on the probability of function in femoropopliteal vein bypass surgery: Analysis of a clinical series (1970 to 1985) and interim evaluation of a controlled clinical trial. Surgery 102:453-459, 1987.

85.

Kretschmer G. , Schemper M. , Ehringer H. , et al. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. Lancet 1:797, 1988.

86.

Arfvidsson B. , Lundgren F. , Drott C. , et al. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery . Am J Surg 159:556-560, 1990.

87.

Hirsh J. , Poller L. , Deykin D. , et al. Optimal therapeutic range for oral anticoagulants. Chest 95:5S-11S, 1989.

88.

Hull R. , Hirsh J. , Jay R. , et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 307:1676-1681, 1982.

89.

Turpie ACG , Gunstensen J. , Hirsh J. , et al. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1:1241, 1988.

90.

Saour JN , Sieck JO , Mamo LAR , Gallus AS Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 322:428, 1990.

91.

Baxter BT , Bergman RT , McCarthy WJ , et al. Prospective assessment of antithrombotic therapy following primary below-knee prosthetic bypass. J Vasc Surg (in press).

92.

Salzman EW , Hirsh J. Prevention of venous thromboembolism. In Colman RW , Hirsh J , Marder VJ , Salzman EW , eds. Hemostasis and Thrombosis, 2nd ed. Philadelphia: JB Lippincott, 1987 , pp 1252-1265.

93.

Clagett GP , Genton E. , Salzman EW , Antithrombotic therapy in peripheral vascular disease. Chest 95:128S-139S, 1989.

94.

Collins GJ Jr , Kimball DB , Rich NM , et al. Heparin utilization during arterial revascularization. Am Surg 44:753-757, 1978.

95.

Effeney DJ , Goldstone J. , Chin D. , et al. Intraoperative anticoagulation in cardiovascular surgery. Surgery 90:1068-1074, 1981.

96.

Weksler BB , Lewin M. Anticoagulation in cerebral ischemia. Stroke 14:658-663, 1983.

97.

Bousser MG , Eschwege E. , Haguenau M. , et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 14:5, 1983.

98.

Canadian Cooperative Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 299:53, 1978.

99.

Fields WS , Lemak N. , Frankowski RF , et al. Controlled trial of aspirin in cerebral ischemia. Stroke 8:301-314, 1977.

100.

Sorensen PS , Pedersen H. , Marquardsen J. , et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attack. A Danish Cooperative Study. Stroke 14:15, 1983.

101.

A. Swedish Cooperative Study. High-dose acetylsalicylic acid after cerebral infarction. Stroke 18:325-334, 1987.

102.

Ramirez-Lassepas M. , Cipolle RJ

Medical treatment of transient ischemic attacks: Does it influence mortality?

Stroke 19:397-400, 1988.

103.

Whisnant JP , Sandok BA , Sundt TM Carotid endarterectomy for unilateral carotid system transient cerebral ischemia. Mayo Clin Proc 58:171-175, 1983.

104.

North American Symptomatic Carotid Endarterectomy Study Group. Carotid endarterectomy: Three critical evaluations. Stroke 18:987-989, 1987.

105.

Stratton JR , Zierler E. , Kazmers A. Platelet deposition at carotid endarterectomy sites in humans. Stroke 18:722-727, 1987.

106.

Findlay JM , Lougheed WM , Gentili F. , et al. Effect of perioperative platelet inhibition on postcarotid endarterectomy mural thrombus formation . J Neurosurg 63:693-698, 1985.

107.

Fields WS , Lemak NA , Frankowski RF , Hardy RJ Controlled trial of aspirin in cerebral ischemia. II. Surgical group. Stroke 9:309, 1978.

108.

Clagett GP , Rich NM , McDonald PT , et al. Etiologic factors for recurrent carotid artery stenosis. Surgery 93:313, 1983.

109.

Cossman D. , Callow AD , Stein A. , et al. Early restenosis after carotid endarterectomy . Arch Surg 113:275, 1978.

110.

Reunanen A. , Takkunen H. , Aromass A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 211:249-256, 1982.

111.

Criqui MH , Fronek A. , Barrett-Connor E. , et al. The prevalence of peripheral arterial disease in a defined population . Circulation 71:510-515, 1985.

112.

Jelnes R. , Gaardsting O. , Jensen KH , et al. Fate in intermittent claudication: Outcome and risk factors . Br Med J 293:1137-1140, 1986 .

113.

Steering Committee of the Physicians' Health Study Research Group. Preliminary report: Findings from the aspirin component of the ongoing physicians' health study. N Engl J Med 318:262-264, 1988.

114.

Peto R. , Gray R. , Collins R. , et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 296:313-316, 1988.

115.

Relman AS Aspirin for the primary prevention of myocardial infarction [editorial] . N Engl J Med 318:245-246, 1988.

116.

Boissel JP , Peyrieux JC , Destors JM

Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?

Thromb Haemost 62:681-685, 1989.

117.

Wilentz JR , Sanborn TA , Haudenschild CC , et al. Platelet accumulation in experimental angioplasty: Time course and relation to vascular injury. Circulation 75:636, 1987.

118.

Cunningham DA , Kumar B. , Siegel BA , et al. Aspirin inhibition of platelet deposition at angioplasty sites: Demonstration by platelet scintigraphy . Radiology 151:487, 1984.

119.

Schwartz L. , Bourassa MG , Lesperance J. , et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 318: 1714, 1988 .

120.

Minar E. , Ehringer H. , Ahmadi R. , et al. Platelet deposition at angioplasty sites and its relation to restenosis in human iliac and femoropopliteal arteries. Radiology 170:767-772, 1989.